Sumitomo Mitsui DS Asset Management Company Ltd Has $2.94 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 27.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,114 shares of the biopharmaceutical company’s stock after purchasing an additional 2,619 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Alnylam Pharmaceuticals were worth $2,944,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $390,438,000. Capital International Investors increased its stake in shares of Alnylam Pharmaceuticals by 15.8% in the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after purchasing an additional 488,814 shares in the last quarter. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after acquiring an additional 287,064 shares during the period. Capital Research Global Investors raised its stake in shares of Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after purchasing an additional 214,908 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after buying an additional 201,784 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director David E. I. Pyott sold 32,450 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at $30,013.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at $30,013.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,148 shares of company stock worth $25,658,824. 1.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of research analyst reports. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Evercore ISI raised their target price on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 25th. Wells Fargo & Company raised their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a report on Friday, July 12th. Finally, UBS Group boosted their target price on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday, June 28th. Seven investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $278.59.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $262.69 on Friday. The stock has a market cap of $33.23 billion, a price-to-earnings ratio of -98.02 and a beta of 0.37. The business’s 50-day simple moving average is $255.96 and its 200 day simple moving average is $187.51. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The business’s revenue was up 107.0% on a year-over-year basis. During the same period in the prior year, the business earned ($2.21) EPS. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.